Table 1.
Clinicopathological characteristics of SCAN-B TNBC patients.
| BRCA1 hypermethylated | BRCA1-nulla | non-BRCA1 | |
|---|---|---|---|
| N | 57 | 25 | 155 |
| Age | |||
| <35 years | 14.0% | 28.0% | 0.6% |
| 35–50 years | 28.1% | 12.0% | 11.0% |
| 50–70 years | 47.4% | 52.0% | 43.9% |
| ≥70 years | 10.5% | 8.0% | 44.5% |
| Germline BRCA1 variantb | 0% | 76% | 0% |
| Tumor size | |||
| ≤20 mm | 57.9% | 52.0% | 47.7% |
| >20 mm | 42.1% | 48.0% | 52.3% |
| Nodal status | |||
| Node negative | 70.2% | 48.0% | 65.2% |
| Node positive | 28.1% | 48.0% | 34.2% |
| Missing data | 1.8% | 4.0% | 0.6% |
| Tumor grade | |||
| Grade 2 | 0% | 0% | 18.1% |
| Grade 3 | 98.2% | 96.0% | 80.0% |
| Missing data | 1.8% | 4.0% | 1.9% |
| ER-staining positivityc | |||
| <1% | 89.5% | 84.0% | 87.6% |
| 1–10% | 10.5% | 16.0% | 12.4% |
| Therapyd | |||
| Chemotherapy | 87.5% | 91.7% | 66.9% |
| Untreated | 12.5% | 8.3% | 33.1% |
| IDFS evente | 17.5% | 28.0% | 38.7% |
| Median IDFS for patients (years)f | 5.0 (0.1–7.1) | 4.8 (0.2–6.7) | 4.6 (0.6–7.2) |
| DRFI evente | 10.5% | 20.0% | 24.5% |
| Median DRFI for patients (years)f | 4.6 (0.1–7) | 4.1 (0.05–6.6) | 4.3 (0.4–7.2) |
| Death eventE | 14.0% | 24.0% | 31.6% |
| Median OS for patients (years)f | 4.7 (0.2–7.1) | 4.1 (2.9–6.8) | 4.6 (2.7–7.1) |
Data obtained from the Swedish national breast cancer quality registry. Cases with missing data omitted from calculations if not shown as separate variable.
aBRCA1-null includes cases with both germline and somatic BRCA1 inactivating genetic variants.
bBased on whole genome sequencing data.
cIn Sweden, ER-negativity is defined as ≤10% of cells with IHC-staining for ER.
dIncludes all cases irrespective if eligible for outcome analysis, but excluding cases with palliative treatment.
eIncludes all events, irrespective of eligibility for outcome analysis.
fTime and range for patients without an event, irrespective of eligibility for outcome analysis.